DailyStocks Stock Article Search

https://www.fool.com/earnings/call-transcripts/2024/10/31/anheuser-busch-inbevnv-bud-q3-2024-earnings-call-t/?source=iedfolrf0000001 Oct 31, 2024 - BUD earnings call for the period ending September 30, 2024. 0

https://seekingalpha.com/article/4727657-fallen-angels-new-downgrades-end-seven-month-drought?source=feed_tag_etf_portfolio_strategy Oct 18, 2024 - The seven-month drought of fallen angles ended in September as OCI NV and VF Corporation were downgraded to high yield, adding approximately $2.4bn in face value to the index. 0

https://www.zacks.com/commentary/2334072/top-stock-reports-for-visa-abbvie-anheuser-busch?cid=CS-ZC-FT-research_daily-2334072 Sep 10, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG). 0

https://www.zacks.com/stock/news/2334138/relay-stock-soars-on-upbeat-data-from-breast-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334138 Sep 10, 2024 - RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC. 0

https://www.zacks.com/stock/news/2334045/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334045 Sep 10, 2024 - BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg. 0

https://www.zacks.com/stock/news/2333625/travere-gains-11-on-securing-full-fda-nod-for-kidney-disease-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333625 Sep 09, 2024 - The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities. 0

https://www.zacks.com/stock/news/2332674/novartis-to-license-vygr-s-capsid-for-gene-therapy-in-neurology?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332674 Sep 06, 2024 - NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target. 0

https://seekingalpha.com/news/4147287-voyager-stock-gains-novartis-licenses-capsid?source=feed_sector_healthcare Sep 05, 2024 - Voyager Therapeutics (VYGR) stock gains as Novartis (NVS) licenses its gene therapy component for rare neurologic disease. Read more here. 0

https://www.zacks.com/stock/news/2331584/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2331584 Sep 04, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option? 0

https://www.zacks.com/stock/news/2329558/are-construction-stocks-lagging-arcadis-arcay-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2329558 Aug 30, 2024 - Here is how Arcadis NV (ARCAY) and Bellway (BLWYY) have performed compared to their sector so far this year. 0